Literature DB >> 29863672

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method.

Morgan A Wambaugh1, Jessica C S Brown2.   

Abstract

Although antimicrobial drugs have dramatically increased the lifespan and quality of life in the 20th century, antimicrobial resistance threatens our entire society's ability to treat systemic infections. In the United States alone, antibiotic-resistant infections kill approximately 23,000 people a year and cost around 20 billion USD in additional healthcare. One approach to combat antimicrobial resistance is combination therapy, which is particularly useful in the critical early stage of infection, before the infecting organism and its drug resistance profile have been identified. Many antimicrobial treatments use combination therapies. However, most of these combinations are additive, meaning that the combined efficacy is the same as the sum of the individual antibiotic efficacy. Some combination therapies are synergistic: the combined efficacy is much greater than additive. Synergistic combinations are particularly useful because they can inhibit the growth of antimicrobial drug resistant strains. However, these combinations are rare and difficult to identify. This is due to the sheer number of molecules needed to be tested in a pairwise manner: a library of 1,000 molecules has 1 million potential combinations. Thus, efforts have been made to predict molecules for synergy. This article describes our high-throughput method for predicting synergistic small molecule pairs known as the Overlap2 Method (O2M). O2M uses patterns from chemical-genetic datasets to identify mutants that are hypersensitive to each molecule in a synergistic pair but not to other molecules. The Brown lab exploits this growth difference by performing a high-throughput screen for molecules that inhibit the growth of mutant but not wild-type cells. The lab's work previously identified molecules that synergize with the antibiotic trimethoprim and the antifungal drug fluconazole using this strategy. Here, the authors present a method to screen for novel synergistic combinations, which can be altered for multiple microorganisms.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29863672      PMCID: PMC6101300          DOI: 10.3791/57241

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  24 in total

1.  Phenotypic landscape of a bacterial cell.

Authors:  Robert J Nichols; Saunak Sen; Yoe Jin Choo; Pedro Beltrao; Matylda Zietek; Rachna Chaba; Sueyoung Lee; Krystyna M Kazmierczak; Karis J Lee; Angela Wong; Michael Shales; Susan Lovett; Malcolm E Winkler; Nevan J Krogan; Athanasios Typas; Carol A Gross
Journal:  Cell       Date:  2010-12-23       Impact factor: 41.582

Review 2.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

3.  Synergy assessed by checkerboard. A critical analysis.

Authors:  M H Hsieh; C M Yu; V L Yu; J W Chow
Journal:  Diagn Microbiol Infect Dis       Date:  1993 May-Jun       Impact factor: 2.803

4.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease.

Authors:  Leah E Cowen; Sheena D Singh; Julia R Köhler; Cathy Collins; Aimee K Zaas; Wiley A Schell; Hamza Aziz; Eleftherios Mylonakis; John R Perfect; Luke Whitesell; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

5.  Mapping the Hsp90 genetic interaction network in Candida albicans reveals environmental contingency and rewired circuitry.

Authors:  Stephanie Diezmann; Magali Michaut; Rebecca S Shapiro; Gary D Bader; Leah E Cowen
Journal:  PLoS Genet       Date:  2012-03-15       Impact factor: 5.917

6.  Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole.

Authors:  Michaela Spitzer; Emma Griffiths; Kim M Blakely; Jan Wildenhain; Linda Ejim; Laura Rossi; Gianfranco De Pascale; Jasna Curak; Eric Brown; Mike Tyers; Gerard D Wright
Journal:  Mol Syst Biol       Date:  2011-06-21       Impact factor: 11.429

7.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Authors:  Kevin Pethe; Patricia C Sequeira; Sanjay Agarwalla; Kyu Rhee; Kelli Kuhen; Wai Yee Phong; Viral Patel; David Beer; John R Walker; Jeyaraj Duraiswamy; Jan Jiricek; Thomas H Keller; Arnab Chatterjee; Mai Ping Tan; Manjunatha Ujjini; Srinivasa P S Rao; Luis Camacho; Pablo Bifani; Puiying A Mak; Ida Ma; S Whitney Barnes; Zhong Chen; David Plouffe; Pamela Thayalan; Seow Hwee Ng; Melvin Au; Boon Heng Lee; Bee Huat Tan; Sindhu Ravindran; Mahesh Nanjundappa; Xiuhua Lin; Anne Goh; Suresh B Lakshminarayana; Carolyn Shoen; Michael Cynamon; Barry Kreiswirth; Veronique Dartois; Eric C Peters; Richard Glynne; Sydney Brenner; Thomas Dick
Journal:  Nat Commun       Date:  2010-08-24       Impact factor: 14.919

8.  Systematic exploration of synergistic drug pairs.

Authors:  Murat Cokol; Hon Nian Chua; Murat Tasan; Beste Mutlu; Zohar B Weinstein; Yo Suzuki; Mehmet E Nergiz; Michael Costanzo; Anastasia Baryshnikova; Guri Giaever; Corey Nislow; Chad L Myers; Brenda J Andrews; Charles Boone; Frederick P Roth
Journal:  Mol Syst Biol       Date:  2011-11-08       Impact factor: 11.429

9.  An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal Pathogens.

Authors:  Nicole Robbins; Michaela Spitzer; Tennison Yu; Robert P Cerone; Anna K Averette; Yong-Sun Bahn; Joseph Heitman; Donald C Sheppard; Mike Tyers; Gerard D Wright
Journal:  Cell Rep       Date:  2015-11-05       Impact factor: 9.423

10.  Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections.

Authors:  Adrián Rangel-Vega; Lawrence R Bernstein; Edna Ayerim Mandujano-Tinoco; Silvia Julieta García-Contreras; Rodolfo García-Contreras
Journal:  Front Microbiol       Date:  2015-04-09       Impact factor: 5.640

View more
  1 in total

1.  Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.

Authors:  Morgan A Wambaugh; Steven T Denham; Magali Ayala; Brianna Brammer; Miekan A Stonhill; Jessica Cs Brown
Journal:  Elife       Date:  2020-05-05       Impact factor: 8.140

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.